On June 3, 2025, Legend Biotech shared new 5-year survival data from the CARTITUDE-1 study, revealing that one-third of multiple myeloma patients were progression-free for at least 5 years after a single infusion of CARVYKTI®. This data was presented at the 2025 ASCO Annual Meeting, showcasing significant long-term outcomes for patients with relapsed/refractory multiple myeloma.